A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 45
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : RAM
Long Form : ramucirumab
No. Year Title Co-occurring Abbreviation
2020 A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab. SOX
2020 Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment. DTX, NSCLC, OS, PFS
2020 Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. AFL, FOLFIRI, LYs, mCRC, QALYs
2020 Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. ICER, LYs, PAC, PLA, QALYs, WTP
2020 Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib. AFP, DCR, LEN, mALBI, PFS, SD, SOR, uHCC
2020 Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. AGC, nab, OS, PFS, PTX, sb
2020 The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel. BM, DOC, EGFR, NSCLC, PFS, TTF
2020 Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group. nab-PTX, OS, PFS, PS, w-nab-PTX, wPTX
2020 [A Thoracic Aortic Dissection Case during Treatment with Ramucirumab plus Nab-Paclitaxel]. nab-PTX
10  2020 [Administering Ramucirumab Safely after Inserting an Intestinal Stent, Due to Peritoneal Metastasis of Gastric Cancer-A Case Report]. VEGFR2
11  2019 Antiangiogenic Human Monoclonal Antibody Ramucirumab Radiolabelling: In Vitro Evaluation on VEGFR2-positive Cell Lines. HPLC, ITLC, mAbs
12  2019 Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer. OS, PFS, PTX
13  2019 Efficacy and safety of Ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: Involvement of angiogenic and immunomodulatory signaling. CFA, MTX, RA
14  2019 Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. GEA, OS, PAC, PFS, pts
15  2019 Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer. AGC, GC, PlGF, PTX
16  2019 Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. DOC, ICIs, NSCLC, PD-L1, PFS
17  2019 Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. FOLFIRI, mCRC, OS, PFS
18  2019 [A Case of Advanced Gastric Cancer Treated Effectively with Combination Chemotherapy of Paclitaxel plus Ramucirumab]. CR, PTX
19  2019 [A Case of Gastric Cancer with Ramucirumab-Related Colon Perforation after a Subtotal Colectomy]. PTX
20  2019 [A Case of Lung Metastases from Rectal Cancer Treated for Quite Long with FOLFIRI plus Ramucirumab as a Late Line of Therapy]. BV
21  2019 [A Case of Multimodality Treatment Including Carbon Ion Radiotherapy to Multiple Distant Lymph Node Metastasis after a Surgery for Sigmoid Cancer]. Bmab, Cmab, RFA
22  2019 [A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer]. ---
23  2019 [A Case Report of Inoperable Gastric Cancer with Peritoneal Dissemination, Liver Metastasis, and Lung Metastasis Successfully Treated with Weekly Paclitaxel and Ramucirumab]. CT, EGD, PET-CT, PTX, SOX therapy
24  2019 [Effect of Hypoalbuminemia on Severe Neutropenia Induced by Paclitaxel Monotherapy and Paclitaxel plus Ramucirumab Combination Therapy in Patients with Gastric Cancer]. PTX
25  2019 [Effectiveness of Ramucirumab Therapy for Advanced Gastric Cancer after Stent Placement for Esophagogastric Junction Carcinoma Obstruction-A Case Report]. PTX
26  2019 [Efficacy and Safety of Paclitaxel plus Ramucirumab Therapy for Unresectable or Recurrent Gastric Cancer]. DCR, PD, PR, PTX, RR, SD
27  2019 [Efforts to Reduce the Risk of Febrile Neutropenia and to Increase the Response Rate to Docetaxel and Ramucirumab Therapy in Patients with Non-Small Cell Lung Cancer]. DTX, FN
28  2019 [Locally Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy with Ramucirumab plus Paclitaxel-Case Report]. NAC, PTX, SP
29  2018 Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies. AFP, HCC
30  2018 Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. AC, GNEC, pts, VEGFR2
31  2018 Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer. Cape, CIS, G-GEJ, PL, QOL
32  2018 RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. DOC, UC
33  2018 Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. eTreg cells, GC, PBMCs, TILs
34  2018 [A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel]. CT, PTX
35  2018 [An Elderly Case of Recurrent Neuroendocrine Carcinoma of the Stomach Treated with Ramucirumab]. ---
36  2018 [The Clinical Effect of Ramucirumab in the Treatment of Advanced Gastric Cancer in Our Hospital]. PTX
37  2017 Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. CAP, HRs, ICR, OS, PFS, VEGF
38  2017 Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). DOC, NSCLC, PBO, pts
39  2017 [A Case of Gastric Cancer with Peritoneal Dissemination Effectively Treated with Ramucirumab and Paclitaxel]. PTX
40  2017 [A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy]. Gr, PTX
41  2017 [Three Patients with Gastric Cancer Who Underwent Surgery during Ramucirumab Treatment]. PTX
42  2016 Economics of ramucirumab for metastatic colorectal cancer. NCCN
43  2016 [A Case of an Elderly Patient with Unresectable Gastric Cancer Treated by Paclitaxel and Ramucirumab]. CT, LN, PR, PTX
44  2016 [Clinical Experience of Ramucirumab for Treating Advanced Gastric Cancer]. PTX
45  2014 An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. CI, CRC, PFS, VEGF, VEGFR2